167 related articles for article (PubMed ID: 29980572)
1. Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
Bouillon AS; Ventura Ferreira MS; Awad SA; Richter J; Hochhaus A; Kunzmann V; Dengler J; Janssen J; Ossenkoppele G; Westerweel PE; Te Boekhorst PAW; Mahon FX; Hjorth-Hansen H; Isfort S; Fioretos T; Hummel S; Schemionek M; Wilop S; Koschmieder S; Saußele S; Mustjoki S; Beier F; Brümmendorf TH
Blood Adv; 2018 Jul; 2(13):1572-1579. PubMed ID: 29980572
[TBL] [Abstract][Full Text] [Related]
2. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
3. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.
Drummond M; Lennard A; Brûmmendorf T; Holyoake T
Leuk Lymphoma; 2004 Sep; 45(9):1775-81. PubMed ID: 15223635
[TBL] [Abstract][Full Text] [Related]
4. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.
Brümmendorf TH; Holyoake TL; Rufer N; Barnett MJ; Schulzer M; Eaves CJ; Eaves AC; Lansdorp PM
Blood; 2000 Mar; 95(6):1883-90. PubMed ID: 10706851
[TBL] [Abstract][Full Text] [Related]
7. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Brummendorf TH; Ersoz I; Hartmann U; Balabanov S; Wolke H; Paschka P; Lahaye T; Berner B; Bartolovic K; Kreil S; Berger U; Gschaidmeier H; Bokemeyer C; Hehlmann R; Dietz K; Lansdorp PM; Kanz L; Hochhaus A
Ann N Y Acad Sci; 2003 May; 996():26-38. PubMed ID: 12799279
[TBL] [Abstract][Full Text] [Related]
8. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
9. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders.
Brümmendorf TH; Rufer N; Holyoake TL; Maciejewski J; Barnett MJ; Eaves CJ; Eaves AC; Young N; Lansdorp PM
Ann N Y Acad Sci; 2001 Jun; 938():293-303; discussion 303-4. PubMed ID: 11458518
[TBL] [Abstract][Full Text] [Related]
10. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Perekhrestenko T; Diachenko M; Sviezhentseva I; Gordienko A; Bilko D
Georgian Med News; 2015 Mar; (240):43-50. PubMed ID: 25879558
[TBL] [Abstract][Full Text] [Related]
12. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
14. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
15. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
[TBL] [Abstract][Full Text] [Related]
16. Flow Cytometry Assessment of CD26
Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
[TBL] [Abstract][Full Text] [Related]
17. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
18. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
19. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover.
Brümmendorf TH; Balabanov S
Leukemia; 2006 Oct; 20(10):1706-16. PubMed ID: 16888616
[TBL] [Abstract][Full Text] [Related]
20. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Morotti A; Panuzzo C; Fava C; Saglio G
Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
